Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2011

View Archived Issues

NICE recommends approval of Votrient as first-line therapy for kidney cancer

Studies of CGI-1746 underscore therapeutic potential of BTK inhibition in rheumatoid arthritis

Mechanism of action of darinaparsin in Hodgkin's and T-cell lymphomas clarified

FdUMP[10] is active against acute myeloid leukemia in vitro and in vivo

New target identified for treatment of psoriasis-associated skin inflammation

AMRI and Genentech enter licensing agreement for antibacterial agents

Kiadis Pharma and Hospira collaborate to develop ATIR

Vaccinex begins phase I trial of VX15/2503 in solid tumors

Spectrum Pharma submits sNDA to FDA for Fusilev in colorectal cancer

Santaris expands alliance with Pfizer for RNA-targeted medicines

Novel 3-dehydroquinate dehydratase inhibitors discovered

Fidaxomicin receives FDA orphan drug status for pediatric CDI

GSK claims new lysophospholipid S1P1 receptor agonists

Allon Therapeutics agrees on SPA for phase II/III davunetide trial in supranuclear palsy

Xoma and Servier sign agreement for anti-inflammatory candidate XOMA-052

New inhibitors of serine/threonine-protein kinase 6 discovered

Isis Pharma launches phase II program for ISIS-EIF4ERx in cancer

Takeda discloses new agonists of free fatty acid FFA1 receptor

CardioVascular BioTherapeutics presents phase II data on CVBT-141B

Bayer begins phase II trial of BAY-86-9766 and sorafenib in liver cancer

PharmaMar begins phase II trial of PM-00104 in Ewing's sarcoma

Genocea Biosciences raises funds to support vaccine development

Wyeth patents new 11-beta-HSD1 inhibitors

Alnylam reports new phase I data on RNAi therapeutic ALN-VSP

Novavax begins phase I study to evaluate RSV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...